Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 2, 2013, Pages 225-237

  Kansal, Anuraag R ^a   Zheng, Ying ^a   Pokora, Tiffany ^a   Sorensen, Sonja V ^a  

^a EVIDERA   (United States)

Author keywords

apixaban; atrial fibrillation; cost effectiveness; dabigatran; rivaroxaban; stroke; warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

CEREBROVASCULAR ACCIDENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL;

EID: 84882266252     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.07.012     Document Type: Review

References (44)

1. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association Europace 14 10 2012 1385 1413 [Epub 2012/08/28]
2. G.Y. Lip, C.M. Brechin, and D.A. Lane The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe Chest 142 6 2012 1489 1498 [Epub 2012/03/31]
3. S.E. Wolowacz, M. Samuel, and V.K. Brennan The cost of illness of atrial fibrillation: a systematic review of the recent literature Europace 13 10 2011 1375 1385 [Epub 2011/07/16]
4. R. Luengo-Fernandez, G.S. Yiin, and A.M. Gray Population-based study of acute- and long-term care costs after stroke in patients with AF Int J Stroke 2012 [Epub 2012/05/10]
5. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics-2012 update: a report from the American Heart Association Circulation 125 1 2012 e2 e220 [Epub 2011/12/20]
6. A.C. Skanes, J.S. Healey, and J.A. Cairns Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2 2012 125 136 [Epub 2012/03/22]
7. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 57 11 2011 1330 1337 [Epub 2011/02/18]
8. R.S. Braithwaite, D.O. Meltzer, and J.T. King Jr. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46 4 2008 349 356 [Epub 2008/03/26]
9. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 5 2004 437 452 [Epub 2004/05/06]
10. J. Pink, S. Lane, and M. Pirmohamed Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses BMJ (Online) 343 2011 7830
11. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151 [Epub 2009/09/01]
12. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Randomized evaluation of long-term anticoagulation therapy I. Newly identified events in the RE-LY trial N Engl J Med 363 19 2010 1875 1876 [Epub 2010/11/05]
13. R. Patel, and M. Medow Cost-effectiveness based pricing for dabigatran for the primary prophylaxis of stroke in elderly patients with atrial fibrillation J Gen Intern Med 25 2010 S249
14. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992 [Epub 2011/08/30]
15. S. Lee, M.W. Anglade, and J. Meng Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin Circ Cardiovasc Qual Outcomes 5 4 2012 472 479
16. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 9 2011 806 817 [Epub 2011/02/12]
17. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 22 2011 2562 2570
18. T. Davidson, M. Husberg, and M. Janzon Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden Eur Heart J 34 3 2013 177 183
19. J.V. Freeman, R.P. Zhu, and D.K. Owens Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 1 2011 1 11
20. H. Kamel, S.C. Johnston, and J.D. Easton Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Stroke 43 3 2012 881 883
21. S.V. Sorensen, A.R. Kansal, and S. Connolly Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Thromb Haemost 105 5 2011 908 919
22. J.H.S. You, K.K.N. Tsui, and R.S.M. Wong Cost-effectiveness of Dabigatran versus genotype-guided management of Warfarin therapy for stroke prevention in patients with Atrial fibrillation PLoS One 7 6 2012
23. J.R. Gonzalez-Juanatey, J. Alvarez-Sabin, and J.M. Lobos Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain Rev Esp Cardiol 65 10 2012 901 910
24. A.R. Kansal, S.V. Sorensen, and R. Gani Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Heart 98 7 2012 573 578
25. L.K. Langkilde, M. Bergholdt Asmussen, and M. Overgaard Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark J Med Econ 15 4 2012 695 703
26. M. Pletscher, R. Plessow, and K. Eichler Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland Swiss Med Wkly 143 2013 w13732 [Epub 2013/01/10]
27. H. Wouters, V. Thijs, and L. Annemans Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium J Med Econ 16 3 2013 407 414
28. J. Karnon, J. Stahl, and A. Brennan Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4 Med Decision Making 32 5 2012 701 711 [Epub 2012/09/20]
29. Pradaxa. Dabigatran etexilate capsules product monograph 2010 Boehringer Ingelheim Canada Ltd [2011 March 11]; Available from: http://www.boehringer- ingelheim.ca/en/Home/Human-Health/Our-Products/Product-Monographs/Pradax-pm.pdf
30. European Medicines Agency European Public assessment report: Pradaxa 2011 [4 Oct 2011]; Available from: http://www.ema.europa.eu/ema/index.jsp?curlpages/ medicines/human/medicines/000829/human-med-000981.jsp&murlmenus/medicines/ medicines.jsp&midWC0b01ac058001d125
31. S. DeWilde, I.M. Carey, and C. Emmas Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care Heart 92 8 2006 1064 1070 [Epub 2006/01/03]
32. R. Parkash, V. Wee, and M.J. Gardner The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study Can J Cardiol 23 2007 457 461
33. H. Kamel, J.D. Easton, and S.C. Johnston Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation Neurology 79 14 2012 1428 1434
34. S. Lee, M.W. Anglade, and D. Pham Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation Am J Cardiol 110 6 2012 845 851
35. S. Lee, R. Mullin, and J. Blazawski Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation PLoS One 7 10 2012
36. A.R. Kansal, M. Sharma, and C. Bradley-Kennedy Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Thromb Haemost 108 4 2012 672 682
37. P. Dorian, T. Kongnakorn, and H. Phatak Cost-effectiveness of apixaban against current standard of care (SoC) for stroke prevention in atrial fibrillation patients Eur Heart J 33 2012 969
38. A.K. Kapur, I. Chatzitheofilou, and L.K. Schang Cost-effectiveness of rivaroxaban compared with warfarin for stroke prevention in atrial fibrillation Value Health 15 4 2012 A122
39. G. Lip, T. Larsen, and F. Skjøth Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Epub ahead of print J Am Coll Cardiol 2012
40. S. Mantha, and J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 3 2012 476 484 [Epub 2012/06/29]
41. L. Testa, M. Agnifili, and R.A. Latini Adjusted indirect compar ison of new oral anticoagulants for stroke prevention in atrial fibrillation QJM 105 10 2012 949 957 [Epub 2012/07/10]
42. S.V. Sorensen, S. Peng, and B.U. Monz A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation Pharmacoeconomics 31 7 2013 589 604
43. T.B. Larsen, L.H. Rasmussen, and F. Skjoth Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: a prospective nationwide cohort study J Am Coll Cardiol 2013 [Epub 2013/04/09]
44. A.M. Chang, J.C. Ho, and B.P. Yan Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation-a real patient data analysis in a Hong Kong Teaching Hospital Clin Cardiol 2013 [Epub 2013/03/16]